Bimatoprost
drugOn this page
Also known as AGN 192024AGN-192024Bimatoprost component of ganfortDurystaLatisseLumiganProstamideUS9271961
Summary
Bimatoprost (CHEMBL1200963) is an approved small-molecule antiglaucoma drug (ATC S01EE03) targeting PTGFR; indicated across 10 conditions including open-angle glaucoma and ocular hypertension.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: S01EE03
- Targets: 1 (PTGFR)
- Indications: 10 conditions
- Clinical trials: 98
- Chemistry: 415.6 Da · C25H37NO4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200963 |
| Name | Bimatoprost |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5311027 |
| ChEBI | CHEBI:51230 |
| ATC | S01EE03 |
| Molecular formula | C25H37NO4 |
| Molecular weight | 415.6 |
| InChIKey | AQOKCDNYWBIDND-FTOWTWDKSA-N |
SMILES: CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
IUPAC name: (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
Pharmacological roles (ChEBI): antiglaucoma drug, antihypertensive agent.
Also known as: AGN 192024, AGN-192024, Bimatoprost, Bimatoprost component of ganfort, Durysta, Latisse, Lumigan, Prostamide, BIMATOPROST, bimatoprost, US9271961
Patent coverage: 2,523 distinct patent families (11,007 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| PTGFR | FP receptor | Full agonist | 5.3 | 0% | P43088 |
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Aldo-keto reductase family 1 member C3, Bile salt export pump.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| AKR1C3 | 5.3 | IC50 | 5000 | nM | CHEMBL_ACT_17758231 |
Target pathways
Aggregated over 1 target gene(s): PTGFR.
Top Reactome pathways
2 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Prostanoid ligand receptors | 1 | PTGFR |
| G alpha (q) signalling events | 1 | PTGFR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| inflammatory response | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| positive regulation of cytosolic calcium ion concentration | 1 |
| parturition | 1 |
| positive regulation of cell population proliferation | 1 |
| positive regulation of gene expression | 1 |
| response to estradiol | 1 |
| response to lipopolysaccharide | 1 |
| negative regulation of apoptotic process | 1 |
| cellular response to prostaglandin D stimulus | 1 |
| signal transduction | 1 |
| response to lipid | 1 |
Indications & clinical
Indications
10 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| open-angle glaucoma | 4 | MONDO:0005338 | EFO:0004190 |
| ocular hypertension | 4 | MONDO:0006875 | EFO:1001069 |
| hypotrichosis | 4 | MONDO:0003037 | MONDO:0003037 |
| glaucoma | 4 | MONDO:0005041 | MONDO:0005041 |
| androgenetic alopecia | 2 | MONDO:0005339 | EFO:0004191 |
| alopecia | 2 | MONDO:0004907 | MONDO:0004907 |
| alopecia areata | 1 | MONDO:0005340 | EFO:0004192 |
| vitiligo | 0 | MONDO:0008661 | EFO:0004208 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 98.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 39 |
| PHASE3 | 21 |
| Not specified | 14 |
| PHASE2 | 13 |
| PHASE1/PHASE2 | 4 |
| PHASE1 | 3 |
| EARLY_PHASE1 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06761313 | PHASE4 | ACTIVE_NOT_RECRUITING | Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma |
| NCT07217678 | PHASE4 | RECRUITING | Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use |
| NCT00273455 | PHASE4 | COMPLETED | Lumigan Versus Cosopt |
| NCT00347802 | PHASE4 | COMPLETED | Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004% |
| NCT00347841 | PHASE4 | COMPLETED | Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost |
| NCT00348023 | PHASE4 | COMPLETED | Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension |
| NCT00348062 | PHASE4 | COMPLETED | A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension |
| NCT00355446 | PHASE4 | COMPLETED | Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous. |
| NCT00440011 | PHASE4 | COMPLETED | Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% |
| NCT00486486 | PHASE4 | COMPLETED | 24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination |
| NCT00539526 | PHASE4 | COMPLETED | Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues |
| NCT00541242 | PHASE4 | COMPLETED | Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension |
| NCT00705757 | PHASE4 | COMPLETED | The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye |
| NCT00847483 | PHASE4 | COMPLETED | Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US |
| NCT01170884 | PHASE4 | COMPLETED | Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® |
| NCT01202513 | PHASE4 | WITHDRAWN | Topical Bimatoprost Solution 0.03%in Stable Vitiligo |
| NCT01229423 | PHASE4 | COMPLETED | Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects |
| NCT01243567 | PHASE4 | COMPLETED | Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated |
| NCT01271686 | PHASE4 | COMPLETED | 24-hour IOP-lowering Effect of 0.01% Bimatoprost |
| NCT01298700 | PHASE4 | COMPLETED | Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension |
| NCT01387906 | PHASE4 | COMPLETED | Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo |
| NCT01448837 | PHASE4 | COMPLETED | 24-Hour Intraocular Pressure Control With Bimatoprost/Timolol Versus Latanoprost as First Choice |
| NCT01464424 | PHASE4 | COMPLETED | Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) |
| NCT01594970 | PHASE4 | COMPLETED | A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) |
| NCT01655758 | PHASE4 | COMPLETED | 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension |
| NCT01664039 | PHASE4 | COMPLETED | An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® |
| NCT01833741 | PHASE4 | COMPLETED | A Study of LUMIGAN® RC in the Clinical Setting |
| NCT01881126 | PHASE4 | COMPLETED | An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension |
| NCT01975714 | PHASE4 | COMPLETED | Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study |
| NCT01978015 | PHASE4 | COMPLETED | Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG |
| NCT02017327 | PHASE4 | COMPLETED | Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose |
| NCT02020512 | PHASE4 | COMPLETED | A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension |
| NCT02059655 | PHASE4 | COMPLETED | Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) |
| NCT02061683 | PHASE4 | COMPLETED | A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension |
| NCT02097719 | PHASE4 | COMPLETED | Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension |
| NCT02571712 | PHASE4 | COMPLETED | Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension |
| NCT03487042 | PHASE4 | UNKNOWN | Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo |
| NCT03966560 | PHASE4 | COMPLETED | Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma |
| NCT04981886 | PHASE4 | UNKNOWN | Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma |
| NCT00300443 | PHASE2/PHASE3 | COMPLETED | Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
13 molecules share ≥1 primary target. Top 13 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| DINOPROST | ChEMBL + PubChem | Phase 4 (approved) | PTGFR |
| DINOPROSTONE | ChEMBL + PubChem | Phase 4 (approved) | PTGFR |
| LAROPIPRANT | ChEMBL | Phase 4 (approved) | PTGFR |
| SEPETAPROST | ChEMBL | Phase 3 | PTGFR |
| CLOPROSTENOL | ChEMBL + PubChem | Phase 2 (approved) | PTGFR |
| EBOPIPRANT | ChEMBL | Phase 2 | PTGFR |
| FLUPROSTENOL | ChEMBL | Phase 2 | PTGFR |
| Belzutifan | PubChem | Approved | PTGFR |
| Grapiprant | PubChem | Approved | PTGFR |
| Latanoprost | PubChem | Approved | PTGFR |
| Latanoprostene Bunod | PubChem | Approved | PTGFR |
| Nitroglycerin | PubChem | Approved | PTGFR |
| Tafluprost | PubChem | Approved | PTGFR |
Related Atlas pages
- Genes: PTGFR
- Diseases: open-angle glaucoma, ocular hypertension, hypotrichosis, glaucoma
- Drugs: Dinoprost, Dinoprostone, Laropiprant, Sepetaprost, Belzutifan, Latanoprost, Latanoprostene Bunod, Nitroglycerin, Tafluprost